BeOne Medicines AG (NASDAQ:ONC) is one of the most promising healthcare stocks according to Wall Street analysts. On June 3, Citizens kept its Market Outperform rating and $396 price target on BeOne Medicines AG (NASDAQ:ONC). The firm made the call after BeOne presented robust tumor clinical data at the American Society of Clinical Oncology (ASCO) 2026 conference.
Citizens said that data for three drugs in BeOne’s pipeline caught its attention. The first was BGB-43395, which BeOne is testing in a common and hard-to-treat form of breast cancer known as HR+/HER2- metastatic breast cancer. The other two are BG-C9074, an antibody-drug conjugate targeting ovarian cancer maintenance and BGB-B2033, a bispecific antibody that BeOne is evaluating in liver cancer.
Citizens noted that in its view, what makes the pipeline noteworthy is that each of these drugs is going after patient populations where current treatments are either too toxic, face resistance problems, or simply do not exist. For that reason, the firm sees BeOne at an inflection point where its tumor strategy is no longer just theoretical.
The firm said it arrived at the $396 price target through a discounted earnings and revenue multiple analysis. It added that it has confidence in BeOne funding its ambitious pipeline because the company holds $4.85 billion in cash, carries more cash than debt, and generates gross profit margins of 88%.
BeOne Medicines AG (NASDAQ:ONC) is a commercial-stage biopharmaceutical company focused on developing novel therapies for the treatment of cancer. Its pipeline includes candidates designed to address unmet needs in solid tumors and hematologic malignancies.
While we acknowledge the potential of ONC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 High-Growth Micro-Cap Stocks to Buy Now and 10 Best Long-Term Stocks to Invest In According to Bill & Melinda Gates Foundation Trust.
Disclosure: None. Follow Insider Monkey on Google News.